Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
GGZ Rivierduinen Eating Disorders Ursula, Leiden, South Holland, The Netherlands.
Int J Eat Disord. 2023 Jan;56(1):80-90. doi: 10.1002/eat.23824. Epub 2022 Oct 13.
We assessed eating disorder (ED) illness status, symptomatology, treatment access, anxiety, and depression in the first year of the COVID-19 pandemic among individuals with a pre-existing ED in the United States (US), the Netherlands (NL), and Sweden (SE).
Participants completed online surveys in April-July 2020, at the early stage of the pandemic, and one year later. At one-year follow-up, we added questions addressing retrospective changes in ED symptoms, treatment, and anxiety/depression since the start of the COVID-19 pandemic. We present descriptive statistics and assess change in ED symptomatology, treatment, and anxiety/depression among those with an active or lingering ED.
Participants (US n = 132; NL n = 219; SE n = 702) were mostly young and female with a history of anorexia nervosa (>60% in all three countries). Across countries, respondents reported impact of COVID-19 on ED symptoms at both time points, with improvement in US and NL at one-year follow-up, and stable but less impact on ED symptoms in SE. Furthermore, at one-year follow-up, roughly half of those in treatment reported reduced treatment access and quality, and the majority of the sample reported increased anxiety and depressive mood since the start of the pandemic.
Our findings suggest that the self-perceived impact of COVID-19 changed over time but remained concerning even one year after the start of the pandemic. Clinicians, community organizations, and policy makers are encouraged to address potentially changing treatment needs in the face of public health emergency events.
Our findings suggest that the impact of COVID-19 on individuals with eating disorders decreased over time but remained concerning even one year after the start of the pandemic and that the impact differed across countries. Clinicians, community organizations, and policy makers are encouraged to incorporate this knowledge to address potentially changing treatment needs in the face of public health emergency events.
本研究在美国、荷兰和瑞典评估了 COVID-19 大流行期间患有既往饮食障碍（ED）的个体的 ED 疾病状况、症状、治疗途径、焦虑和抑郁。
参与者于 2020 年 4 月至 7 月（大流行早期）和一年后在线完成了调查。在一年的随访中，我们增加了一些问题，以评估自 COVID-19 大流行开始以来 ED 症状、治疗和焦虑/抑郁的变化。我们呈现了描述性统计数据，并评估了那些有活跃或持续 ED 的个体的 ED 症状、治疗和焦虑/抑郁的变化。
参与者（美国 n=132；荷兰 n=219；瑞典 n=702）以年轻和女性为主，且既往有神经性厌食症病史（三国均超过 60%）。在所有三个国家，受访者都报告了 COVID-19 对 ED 症状的影响，且美国和荷兰在一年的随访中有所改善，而瑞典的 ED 症状则保持稳定但影响较小。此外，在一年的随访中，大约一半接受治疗的人报告治疗途径和质量下降，且大多数样本报告自大流行开始以来焦虑和抑郁情绪增加。
我们的研究结果表明，COVID-19 的自我感知影响随时间而变化，但即使在大流行开始一年后仍令人担忧。鼓励临床医生、社区组织和政策制定者在面对公共卫生紧急事件时解决潜在的不断变化的治疗需求。
我们的研究结果表明，COVID-19 对饮食障碍患者的影响随时间推移而降低，但即使在大流行开始一年后仍令人担忧，且影响因国家而异。鼓励临床医生、社区组织和政策制定者了解这方面的知识，以便在面对公共卫生紧急事件时解决潜在的不断变化的治疗需求。
